CLRB - セレクタ・バイオサイエンシ―ズ （Cellectar Biosciences Inc.） セレクタ・バイオサイエンシ―ズCLRBのチャート
CLRBの企業情報
| symbol | CLRB |
|---|---|
| 会社名 | Cellectar Biosciences Inc （セレクタ・バイオサイエンシ―ズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 Cellectar Biosciences Inc. formerly Novelos Therapeutics Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates including radiotherapeutic and chemotherapeutic PDC''s. The Company''s PDC product portfolio includes CLR 131 which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125 which is for the treatment of micro metastatic disease; CLR 124 which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502 which is for intraoperative tumor margin illumination and non-invasive tumor imaging and CTX Product Portfolio including CLR 1601-PTX CLR 1602-PTX and CLR 1603-PTX product candidates. セレクタ・バイオサイエンシ―ズは米国のバイオ医薬品企業。癌治療薬、癌標的の投影剤の開発に従事。同社の癌注力技術は癌幹細胞を含む癌細胞に対する薬剤の選択的送達を可能にする。開発中の製品候補は、癌標的陽電子放射断層撮影造影剤I-124-CLR1404、癌標的分子放射線治療I-131-CLR1404、非放射光造影剤CLR1502など。 Cellectar Biosciences is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. The company's core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company's PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations. The company's product pipeline includes one preclinical PDC chemotherapeutic program (CLR 1900) and multiple partnered PDC assets. |
| 本社所在地 | 3301 Agriculture Drive Madison WI 53716 USA |
| 代表者氏名 | Stephen Anthony Hill スティーブン・アンソニー・ヒル |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 608-441-8120 |
| 設立年月日 | 35217 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | － |
| url | www.cellectar.com |
| nasdaq_url | https://www.nasdaq.com/symbol/clrb |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -12.53883 |
| 終値（lastsale） | 2.715 |
| 時価総額（marketcap） | 10311094.875 |
| 時価総額 | 時価総額（百万ドル） 10.21615 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 6.03918 |
| 当期純利益 | 当期純利益（百万ドル） -15.39489 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Cellectar Biosciences Inc revenues was not reported. Net loss increased 6% to $6.4M. Higher net loss reflects (Loss)/Gain on revaluation of derivative decrease from $8K (income) to $47K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$4.73 to -$3.75. |
CLRBのテクニカル分析
CLRBのニュース
Cellectar Receives $2M NIH Grant For Rare Lymphoma Study 2021/08/18 15:54:58 Benzinga
Cellectar Biosciences Inc (NASDAQ: CLRB ) has received a peer-reviewed National Institutes of Health (NIH) Phase II Small Business Innovation Research (SBIR) grant of approximately $2 million from the National Cancer Institute (NCI). The Company is currently conducting a pivotal study of iopofosine I-131 Full story available on Benzinga.com
Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom''s Macroglobulinemia 2021/08/18 12:30:00 Benzinga
FLORHAM PARK, N.J., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB ), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced it has been awarded a peer-reviewed National Institutes of Health (NIH) Phase II Small Business Innovation Research (SBIR) grant of approximately $2 Million from the National Cancer Institute (NCI). The company is currently conducting a global pivotal study of iopofosine I-131 (also known as CLR 131) in Waldenstrom''s macroglobulinemia (WM) patients who have received at least two prior lines of therapy, including Bruton tyrosine kinase inhibitor failed or suboptimal response patients. The study was initiated in January of 2021 and is expected to take approximately 18 months to fully enroll. "We appreciate the recognition and funding that the NIH and NCI have chosen to provide Cellectar for our pivotal iopofosine program. WM is an incurable disease with existing treatment options restricted to one approved drug and various unapproved salvage therapies," said James Caruso, president and CEO of Cellectar. "This $2 million non-dilutive grant will be used to support and accelerate the ongoing pivotal study.
Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstroms Macroglobulinemia 2021/08/18 12:30:00 Intrado Digital Media
FLORHAM PARK, N.J., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced it has been awarded a peer-reviewed National Institutes of Health (NIH) Phase II Small Business Innovation Research (SBIR) grant of approximately $2 Million from the National Cancer Institute (NCI).
Impulsive Stock: Bit Digital, Inc. (NASDAQ:BTBT), Cellectar Biosciences, Inc. (NASDAQ:CLRB) 2021/08/17 21:19:21 Stock Equity
Bit Digital, Inc. (NASDAQ:BTBT) with the stream of -5.49% also noticed, India Cellectar Biosciences, Inc. (NASDAQ:CLRB) encountered a rapid change of -2.22% in the last hour of Tuesdays trading session. The post Impulsive Stock: Bit Digital, Inc. (NASDAQ:BTBT), Cellectar Biosciences, Inc. (NASDAQ:CLRB) appeared first on Stocks Equity .
Stock on fire: Cellectar Biosciences, Inc. (NASDAQ:CLRB), Qumu Corporation (NASDAQ:QUMU) 2021/08/17 01:12:59 Stock Equity
Cellectar Biosciences, Inc. (CLRB) with the stream of 4.94% also noticed, India Qumu Corporation (QUMU) encountered a rapid change of 10.80% in the last hour of Mondays trading session. Cellectar The post Stock on fire: Cellectar Biosciences, Inc. (NASDAQ:CLRB), Qumu Corporation (NASDAQ:QUMU) appeared first on Stocks Equity .
Cellectar shares fall after mid-stage CLR 131 trial data fails to impress 2021/06/04 15:10:07 Seeking Alpha
28 Stocks Moving in Tuesday's Pre-Market Session 2021/03/16 11:44:06 Benzinga
Gainers SunLink Health Systems, Inc. (NYSE: SSY ) shares rose 82.4% to $3.52 in pre-market trading as the company reported $2 million expansion, capital and operating improvements at Trace Regional Hospital. NTN Buzztime, Inc. (NYSE: NTN ) rose 50.1% to $5.66 in pre-market trading. NTN Buzztime said its stockholders approved the proposed merger between NTN and Brooklyn ImmunoTherapeutics LLC. Sypris Solutions, Inc. (NASDAQ: SYPR ) rose 46.9% to $5.51 in pre-market trading. Sypris Solutions is expected to release Q4 earnings on March 18. Anchiano Therapeutics Ltd. (NASDAQ: ANCN ) rose 43.2% to $6.40 in pre-market trading after the company reported shareholder approval of the merger with Chemomab. The company also priced its $45.5 million private financing. Enzo Biochem, Inc. (NYSE: ENZ ) shares rose 36.4% to $4.04 in pre-market trading after the company swung to a profit in the second quarter. Savara Inc. (NASDAQ: SVRA ) rose 30% to $2.30 in pre-market trading after the company's CFO disclosed an open market purchase of 13,793 shares at $1.45 per share.
Pediatric Neuroblastoma Treatment Market to Rapidly Growing in Healthcare Sector with Top Key Players: United Therapeutics Corporation, APEIRON Biologics AG, Baxter, CELLECTAR BIOSCIENCES, INC, Sun Pharmaceutical Industries, Pfizer, Bayer AG, MacroGenics 2020/11/25 14:04:57 OpenPR
The Pediatric Neuroblastoma Treatment Market studied was projected to grow with a CAGR of nearly +6% over the forecast period. As per the scope of the report neuroblastoma is cancer that develops from immature nerve cells found in several areas of
Cellectar Reports Third Quarter 2020 Financial Results and Provides a Corporate Update - Stocks News Feed 2020/11/09 13:44:00 Stocks News Feed
FLORHAM PARK, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the third quarter ended September 30, 2020 and provided a corporate update. Third Quarter and Recent Corporate Highlights… Read More »Cellectar Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
Cellectar Biosciences (NASDAQ:CLRB) Stock Crosses Above 50-Day Moving Average of $1.20 2020/10/24 15:58:43 The Olympia Report
Cellectar Biosciences, Inc. (NASDAQ:CLRB)’s share price crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $1.20 and traded as high as $1.24. Cellectar Biosciences shares last traded at $1.20, with a volume of 115,859 shares changing hands. Several analysts have recently weighed in on CLRB […]
Cellectar Biosciences (NASDAQ:CLRB) Stock Price Passes Above Fifty Day Moving Average of $1.20 2020/10/23 02:20:41 US Banking News
Cellectar Biosciences, Inc. (NASDAQ:CLRB)’s share price passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $1.20 and traded as high as $1.24. Cellectar Biosciences shares last traded at $1.20, with a volume of 115,859 shares traded. Several analysts have weighed in on the […]